Press release
Global HIV Infection Pipeline Analysis
Download Report:
http://www.pnspharma.com/buy-report.php?reporttitle=Global-HIV-Infection-Pipeline-Analysis
“Global HIV Infection Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of HIV Infection. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the HIV Infection drug market based upon development process.
Following parameters for each drug profile in clinical development phase are covered in “Global HIV Infection Pipeline Analysis” research report:
• Drug Profile Overview
• Alternate Names for Drug
• Active Indication
• Phase of Development
• Mechanism of Action
• Brand Name
• Patent Information
• Orphan Designation by Indication, Country & Organisation
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route
• Drug Class
• ATC Codes
HIV Infection Drug Development by Clinical Phase:
• Research: 31
• Preclinical: 140
• Phase-I: 53
• Phase-I/II: 18
• Phase-II: 39
• Phase-III: 7
• Preregistration: 2
• Registered: 2
• Marketed: 34
For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com
Recent Publication
* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022
PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.
Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global HIV Infection Pipeline Analysis here
News-ID: 603605 • Views: 374
More Releases from PNS Pharma
Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight:
o Global Gene Therapy Market Opportunity: > US$ 8 Billion
o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials
o Commercially Available Gene Therapies: 11
o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials
o Cancer Accounts For 50% of Global Gene Therapy Trials
Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026
Over the years, gene therapy has been highly responsible for decreasing the mortality rate…
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
More Releases for HIV
Global HIV Market to 2024
The HIV market was valued at $16bn in 2015 and is forecast to expand at a CAGR of 3.7% between 2015 and 2024, culminating in 2024 global sales of $23bn.The expected arrival of new classes of therapies could result in a paradigm shift in the treatment of HIV treatment.
Globally, around 35 million people are infected with HIV. Approximately 3 million people in the U.S and 2.5 million in top 5…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
Global HIV Therapeutics Market
The HIV Therapeutics Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss…
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus.
Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral…
Approaches to HIV Eradication
The various approaches to HIV eradication all address a problem, and that problem is the HIV reservoir. HIV reservoirs have been called the last hiding place for HIV within the body. The final step toward finding a cure against HIV lies in dealing with HIV reservoirs.
Toulon, France, August 30, 2011 - What can be done about HIV eradication? The advancements in scientific technology and medical treatments have made significant progress…
